{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:44:09Z","timestamp":1792575849868,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803549"],"award-info":[{"award-number":["81803549"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017623","name":"Zhejiang Provincial Outstanding Youth Science Foundation","doi-asserted-by":"publisher","award":["LQ18H310002"],"award-info":[{"award-number":["LQ18H310002"]}],"id":[{"id":"10.13039\/501100017623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY656"],"award-info":[{"award-number":["2022KY656"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemoresistance remains a major obstacle to effective treatment of non-small cell lung cancer (NSCLC), yet the epigenetic mechanisms underlying platinum resistance remain incompletely understood. Here, we show that Jumonji C domain-containing protein 5 (JMJD5) promotes platinum resistance in NSCLC cells and xenograft tumors while inducing a slow-proliferative, mesenchymal-like phenotype characterized by enhanced migration, invasion, spheroid formation, and epithelial\u2013mesenchymal transition (EMT). Mechanistically, JMJD5 interacted with RCC1 domain-containing protein 1 (RCCD1), and cisplatin treatment promoted their nuclear accumulation concomitant with reduced H3K36me2 levels. RCCD1 depletion attenuated JMJD5-associated H3K36me2 demethylation and reversed EMT-associated phenotypes and cisplatin resistance, supporting RCCD1 as a functional cofactor of JMJD5-mediated chromatin remodeling. Fibronectin 1 (FN1) was further identified as a downstream effector of this pathway. Genetic or pharmacological inhibition of FN1 suppressed JMJD5-induced migration and invasion and restored cisplatin sensitivity. Notably, JMJD5-dependent FN1 protein accumulation required ongoing protein synthesis without a corresponding increase in FN1 mRNA, suggesting post-transcriptional regulation. Consistently, elevated FN1 expression was associated with unfavorable overall survival in patients with lung cancer. Collectively, these findings reveal a JMJD5\u2013RCCD1\u2013H3K36me2\u2013FN1 regulatory axis linking chemotherapy-induced epigenetic remodeling to EMT-associated platinum resistance and suggest that disruption of this pathway may represent a potential strategy for overcoming chemoresistance in NSCLC.<\/jats:p>","DOI":"10.1186\/s43556-026-00625-y","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:17:36Z","timestamp":1792574256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RCCD1-JMJD5 coordinate histone demethylation to promote platinum resistance in non-small cell lung cancer via FN1-mediated epithelial\u2013mesenchymal transition"],"prefix":"10.1186","volume":"7","author":[{"given":"Lili","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"625_CR2","doi-asserted-by":"publisher","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","DOI":"10.3322\/caac.21871"},{"key":"625_CR3","doi-asserted-by":"publisher","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623\u201340. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013.","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"625_CR4","doi-asserted-by":"publisher","unstructured":"Xiang X, Ma X, Fang M, Zhong L, Liu H, Liu H, et al. Jumonji domain containing 5 is a potential prognostic indicator in non-small cell lung cancer patients who received platinum-based chemotherapy. Transl Cancer Res. 2019;8(7):2535\u201342. https:\/\/doi.org\/10.21037\/tcr.2019.10.16.","DOI":"10.21037\/tcr.2019.10.16"},{"key":"625_CR5","doi-asserted-by":"publisher","unstructured":"Hsia DA, Tepper CG, Pochampalli MR, Hsia EY, Izumiya C, Huerta SB, et al. KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. Proc Natl Acad Sci U S A. 2010;107(21):9671\u20136. https:\/\/doi.org\/10.1073\/pnas.1000401107.","DOI":"10.1073\/pnas.1000401107"},{"key":"625_CR6","doi-asserted-by":"publisher","unstructured":"Wilkins SE, Islam MS, Gannon JM, Markolovic S, Hopkinson RJ, Ge W, et al. JMJD5 is a human arginyl C-3 hydroxylase. Nat Commun. 2018;9(1):1180. https:\/\/doi.org\/10.1038\/s41467-018-03410-w.","DOI":"10.1038\/s41467-018-03410-w"},{"key":"625_CR7","doi-asserted-by":"publisher","unstructured":"Liu H, Ramachandran S, Fong N, Phang T, Lee S, Parsa P, et al. JMJD5 couples with CDK9 to release the paused RNA polymerase II. Proc Natl Acad Sci U S A. 2020;117(33):19888\u201395. https:\/\/doi.org\/10.1073\/pnas.2005745117.","DOI":"10.1073\/pnas.2005745117"},{"key":"625_CR8","doi-asserted-by":"publisher","unstructured":"Liu H, Wang C, Lee S, Deng Y, Wither M, Oh S, et al. Clipping of arginine-methylated histone tails by JMJD5 and JMJD7. Proc Natl Acad Sci U S A. 2017;114(37):E7717\u201326. https:\/\/doi.org\/10.1073\/pnas.1706831114.","DOI":"10.1073\/pnas.1706831114"},{"key":"625_CR9","doi-asserted-by":"publisher","unstructured":"Shen J, Xiang X, Chen L, Wang H, Wu L, Sun Y, et al. JMJD5 cleaves monomethylated histone H3 N-tail under DNA damaging stress. EMBO Rep. 2017;18(12):2131\u201343. https:\/\/doi.org\/10.15252\/embr.201743892.","DOI":"10.15252\/embr.201743892"},{"key":"625_CR10","doi-asserted-by":"publisher","unstructured":"Wu BH, Chen H, Cai CM, Fang JZ, Wu CC, Huang LY, et al. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686. Oncotarget. 2016;7(6):6847\u201363. https:\/\/doi.org\/10.18632\/oncotarget.6867.","DOI":"10.18632\/oncotarget.6867"},{"key":"625_CR11","doi-asserted-by":"publisher","unstructured":"Wang H, Wang J, Liu J, Wang Y, Xia G, Huang X. Jumonji-C domain-containing protein 5 suppresses proliferation and aerobic glycolysis in pancreatic cancer cells in a c-Myc-dependent manner. Cell Signal. 2022;93:110282. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110282.","DOI":"10.1016\/j.cellsig.2022.110282"},{"key":"625_CR12","doi-asserted-by":"publisher","unstructured":"Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, et al. KDM8\/JMJD5 as a dual coactivator of AR and PKM2 integrates AR\/EZH2 network and tumor metabolism in CRPC. Oncogene. 2019;38(1):17\u201332. https:\/\/doi.org\/10.1038\/s41388-018-0414-x.","DOI":"10.1038\/s41388-018-0414-x"},{"key":"625_CR13","doi-asserted-by":"publisher","unstructured":"Song J, Zheng J, Liu X, Dong W, Yang C, Wang D, et al. A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5. J Exp Clin Cancer Res. 2022;41(1):171. https:\/\/doi.org\/10.1186\/s13046-022-02374-6.","DOI":"10.1186\/s13046-022-02374-6"},{"key":"625_CR14","doi-asserted-by":"publisher","unstructured":"Wang HJ, Hsieh YJ, Cheng WC, Lin CP, Lin YS, Yang SF, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1\u03b1-mediated glucose metabolism. Proc Natl Acad Sci U S A. 2014;111(1):279\u201384. https:\/\/doi.org\/10.1073\/pnas.1311249111.","DOI":"10.1073\/pnas.1311249111"},{"key":"625_CR15","doi-asserted-by":"publisher","unstructured":"Shen J, Liu G, Qi H, Xiang X, Shao J. JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation. Cell Death Dis. 2023;14(10):657. https:\/\/doi.org\/10.1038\/s41419-023-06194-0.","DOI":"10.1038\/s41419-023-06194-0"},{"key":"625_CR16","doi-asserted-by":"publisher","unstructured":"Yao Y, Zhou WY, He RX. Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53\/NF-\u03baB pathway. Biomed Pharmacother. 2019;109:1994\u20132004. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.144.","DOI":"10.1016\/j.biopha.2018.07.144"},{"key":"625_CR17","doi-asserted-by":"publisher","unstructured":"Marcon E, Ni Z, Pu S, Turinsky AL, Trimble SS, Olsen JB, et al. Human-chromatin-related protein interactions identify a demethylase complex required for chromosome segregation. Cell Rep. 2014;8(1):297\u2013310. https:\/\/doi.org\/10.1016\/j.celrep.2014.05.050.","DOI":"10.1016\/j.celrep.2014.05.050"},{"key":"625_CR18","doi-asserted-by":"publisher","unstructured":"Liu G, Qi H, Shen J. JMJD5 inhibits lung cancer progression by regulating glucose metabolism through the p53\/TIGAR pathway. Med Oncol. 2023;40(5):145. https:\/\/doi.org\/10.1007\/s12032-023-02016-7.","DOI":"10.1007\/s12032-023-02016-7"},{"key":"625_CR19","doi-asserted-by":"publisher","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44.","DOI":"10.1038\/nrclinonc.2017.44"},{"key":"625_CR20","doi-asserted-by":"publisher","unstructured":"Saw PE, Liu Q, Wong PP, Song E. Cancer stem cell mimicry for immune evasion and therapeutic resistance. Cell Stem Cell. 2024;31(8):1101\u201312. https:\/\/doi.org\/10.1016\/j.stem.2024.06.003.","DOI":"10.1016\/j.stem.2024.06.003"},{"key":"625_CR21","doi-asserted-by":"publisher","unstructured":"Loh JJ, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31(5):617\u201339. https:\/\/doi.org\/10.1016\/j.stem.2024.04.004.","DOI":"10.1016\/j.stem.2024.04.004"},{"key":"625_CR22","doi-asserted-by":"publisher","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124\u201334. https:\/\/doi.org\/10.1038\/nm.4409.","DOI":"10.1038\/nm.4409"},{"key":"625_CR23","doi-asserted-by":"publisher","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525\u201330. https:\/\/doi.org\/10.1038\/nature16064.","DOI":"10.1038\/nature16064"},{"key":"625_CR24","doi-asserted-by":"publisher","unstructured":"Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472\u20136. https:\/\/doi.org\/10.1038\/nature15748.","DOI":"10.1038\/nature15748"},{"key":"625_CR25","doi-asserted-by":"publisher","unstructured":"Fontana R, Mestre-Farrera A, Yang J. Update on epithelial-mesenchymal plasticity in cancer progression. Annu Rev Pathol. 2024;19:133\u201356. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-051222-122423.","DOI":"10.1146\/annurev-pathmechdis-051222-122423"},{"key":"625_CR26","doi-asserted-by":"publisher","unstructured":"Yawut N, Cho IR, Budluang P, Kaowinn S, Kaewpiboon C, Jeon B et al. Elevated Expression of JMJD5 Protein Due to Decreased miR-3656 Levels Contributes to Cancer Stem Cell-Like Phenotypes under Overexpression of Cancer Upregulated Gene 2. Biomolecules. 2022;12(1). https:\/\/doi.org\/10.3390\/biom12010122","DOI":"10.3390\/biom12010122"},{"key":"625_CR27","doi-asserted-by":"publisher","unstructured":"Han S, Lin M, Wu L, Lin X, Chen M, Hu C, et al. E2F1 modulates RCCD1 expression to participate in the initiation and progression of EMT in colorectal cancer. Pathol Res Pract. 2024;260:155429. https:\/\/doi.org\/10.1016\/j.prp.2024.155429.","DOI":"10.1016\/j.prp.2024.155429"},{"key":"625_CR28","doi-asserted-by":"publisher","unstructured":"Wu J, He Z, Yang XM, Li KL, Wang DL, Sun FL. RCCD1 depletion attenuates TGF-\u03b2-induced EMT and cell migration by stabilizing cytoskeletal microtubules in NSCLC cells. Cancer Lett. 2017;400:18\u201329. https:\/\/doi.org\/10.1016\/j.canlet.2017.04.021.","DOI":"10.1016\/j.canlet.2017.04.021"},{"key":"625_CR29","doi-asserted-by":"publisher","unstructured":"Zhang H, Liu Y, Li X, Ding C, Xia C, Huang H, et al. A novel lactylation-related gene signature to predict prognosis and treatment response in lung adenocarcinoma. Front Oncol. 2025;15:1549724. https:\/\/doi.org\/10.3389\/fonc.2025.1549724.","DOI":"10.3389\/fonc.2025.1549724"},{"key":"625_CR30","doi-asserted-by":"publisher","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396. https:\/\/doi.org\/10.1038\/nrm3758.","DOI":"10.1038\/nrm3758"},{"key":"625_CR31","doi-asserted-by":"publisher","unstructured":"Ritzenthaler JD, Han S, Roman J. Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol Biosyst. 2008;4(12):1160\u20139. https:\/\/doi.org\/10.1039\/b800533h.","DOI":"10.1039\/b800533h"},{"key":"625_CR32","doi-asserted-by":"publisher","unstructured":"Jin S, Wang W, Xu X, Yu Z, Feng Z, Xie J, et al. miR-34b-3p-mediated regulation of STC2 and FN1 enhances chemosensitivity and inhibits proliferation in cervical cancer. Acta Biochim Biophys Sin (Shanghai). 2024;56(5):740\u201352. https:\/\/doi.org\/10.3724\/abbs.2024009.","DOI":"10.3724\/abbs.2024009"},{"key":"625_CR33","doi-asserted-by":"publisher","unstructured":"Liang H, Yu M, Yang R, Zhang L, Zhang L, Zhu D, et al. A PTAL-miR-101-FN1 axis promotes EMT and invasion-metastasis in serous ovarian cancer. Mol Ther Oncolytics. 2020;16:53\u201362. https:\/\/doi.org\/10.1016\/j.omto.2019.12.002.","DOI":"10.1016\/j.omto.2019.12.002"},{"key":"625_CR34","doi-asserted-by":"publisher","unstructured":"Liu X, Meng L, Li X, Li D, Liu Q, Chen Y, et al. Regulation of FN1 degradation by the p62\/SQSTM1-dependent autophagy-lysosome pathway in HNSCC. Int J Oral Sci. 2020;12(1):34. https:\/\/doi.org\/10.1038\/s41368-020-00101-5.","DOI":"10.1038\/s41368-020-00101-5"},{"key":"625_CR35","doi-asserted-by":"publisher","unstructured":"Hnasko TS, Hnasko RM. The Western Blot. Methods Mol Biol. 2015;1318:87\u201396. https:\/\/doi.org\/10.1007\/978-1-4939-2742-5_9.","DOI":"10.1007\/978-1-4939-2742-5_9"},{"key":"625_CR36","doi-asserted-by":"publisher","unstructured":"Chen Y, Zhou H, Yang S, Su D. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer. Cell Biochem Funct. 2021;39(2):277\u201386. https:\/\/doi.org\/10.1002\/cbf.3577.","DOI":"10.1002\/cbf.3577"},{"key":"625_CR37","doi-asserted-by":"publisher","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. https:\/\/doi.org\/10.1126\/science.1260419.","DOI":"10.1126\/science.1260419"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00625-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:17:37Z","timestamp":1792574257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00625-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00625-y","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental procedures involving in animals was approved by the Laboratory Animal Ethics Committee of Zhejiang Cancer Hospital (No. zjzlsd-2021\u201304-002).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"222"}}